

LIFE SCIENCE TREND ANALYSIS

Sweden | 2026



invest in skåne



2025 ANALYSIS



ABOUT US



The following statistical information has been obtained from Biotechgate, a global, comprehensive life science database encompassing the biotechnology, pharmaceutical and medical device industries.

www.biotechgate.com



The Swedish Life Sciences Database is a part of the global Biotechgate and is brought to you in partnership with Business Region Göteborg, and Invest in Skåne.

<https://swedishlifesciences.com>



Biotechgate is owned and operated by Venture Valuation AG, a Zurich based company specializing in independent assessment and valuation of technology-driven companies in high growth industries, such as the life sciences (biotech, pharma, medtech), ICT, high-tech, nanotech, cleantech and renewable energy.

www.venturevaluation.com

OUR PARTNERS

invest in skåne



BUSINESS REGION
GÖTEBORG

Invest in Skåne is the official investment promotion agency for Skåne in southern Sweden, helping international companies invest and expand in the region and attracting talent to Skåne and the wider Greater Copenhagen area. The region is part of Medicon Valley, one of Europe's leading life science clusters, and hosts 820 life science companies and 27% of Sweden's national drug pipeline. The Skåne directory, created and run by Biotechgate, showcases organisations across the southern Swedish life sciences ecosystem:



<https://investinskane.com/en/invest/business-sectors-in-skane/life-sciences>

Business Region Göteborg (BRG) is the municipally owned business development company of the Gothenburg region, where life science is a priority area; it promotes innovation, attracts investment and supports the establishment of new life science companies. The region is home to Northern Europe's largest university hospital, one of AstraZeneca's three global strategic R&D centres, and over 500 life science enterprises. The Gothenburg directory, created and run by Biotechgate, showcases companies across the West Swedish life sciences ecosystem:

<https://www.investingothenburg.com/sectors-industries/life-science-gothenburg/life-science-database>

OVERVIEW OF THE LIFE SCIENCE INDUSTRY


NUMBER OF COMPANIES BY SECTOR



For the definition of categories please visit <https://www.biotechgate.com/about/industry-sectors-covered/>. Biotech Companies include the following categories: Biotechnology – Therapeutics and Diagnostics; Biotechnology – R&D; Biotechnology – Other. *Other life science related companies include supplier & engineering, professional services & consulting, media and public / non-profit organizations / medical facilities and media and count as non-core companies in Biotechgate. Percentage value is expressed as % of total number of companies. Information displayed may alter as new information is received continuously


OVERVIEW OF BIOTECH COMPANIES

NUMBER OF COMPANIES BY SECTOR



BIOTECH - THERAPEUTICS COMPANIES BY KEY ACTIVITIES

AS PERCENTAGE OF TOTAL NUMBER OF BIOTECH – THERAPEUTICS AND DIAGNOSTICS COMPANIES




For **180** Biotech Therapeutics companies there were **88** subsectors (key activity areas) assigned (one biotech company can be active in multiple areas). The graph displays Biotech – Therapeutics and Diagnostics subsectors as the percentage of the total number of Biotech – Therapeutics and Diagnostics subsectors with exclusion of the category Others and categories with <2%. The company subsectors are regarded as the key activities of a company. For the definition of subsectors please visit <https://www.biotechgate.com/about/industry-sectors-covered/>. Information displayed may alter as new information is received continuously.


BIOTECH ASSETS IN CLINICAL DEVELOPMENT

BY INDICATION AND DEVELOPMENT PHASE

BREAKDOWN BY INDICATION



BREAKDOWN BY DEVELOPMENT PHASE




Both graphs contain the number of assets of Biotech – Therapeutics and Diagnostics companies (excl. of Pharma or Biotech – Others or Biotech R&D Services companies). Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category. Information displayed in the chart may alter as new information is received continuously

ASSETS AVAILABLE FOR OUT-LICENSING


NUMBER OF ASSETS

BY ASSET CLASS



Therapeutics Diagnostics Medical Devices Technologies

THERAPEUTICS IN DEVELOPMENT
BY DEVELOPMENT PHASE




Preclinical Phase I Phase II

The graph titled Therapeutics in Development by Development Phase displays a subset of the asset class Therapeutics. Products in Discovery and Lead Optimization Phase are merged into Preclinical; Development Phase I/II trials are merged into Phase II and Phase II/III trials are merged into Phase III category.

OVERVIEW OF OWNERSHIP


PERCENTAGE OF TOTAL NUMBER OF COMPANIES BY OWNERSHIP AND SECTOR



For the definition of categories please visit <https://www.biotechgate.com/about/industry-sectors-covered/>. Percentage value is expressed as % of total number of companies in the sector. Information displayed may alter as new information is received continuously.

COMPANY FOUNDATION TIMELINE

NUMBER OF LIFE SCIENCE COMPANIES FOUNDED BY YEAR | 2015-2024




The graph contains the number of privately owned or publicly listed (no subsidiaries) life science companies founded by year including Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others, Pharma, Medical Technology and Digital Health companies. **Companies founded in 2025 were excluded** since newly founded companies often remain under the radar until their first financing round. Information displayed in the chart may alter as new information is received continuously.


VENTURE FINANCING OF LIFE SCIENCE COMPANIES

PRIVATE EQUITY ROUNDS | 2025-2026

LIFE SCIENCE COMPANIES




BIOTECH COMPANIES



Life Science companies include Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech – Others, Pharma, Medical Technology and Digital Health companies. Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutics and Diagnostics, Biotech - R&D Services, Biotech – Others. Financing data only includes private equity rounds (excl. private placements in public companies). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

BIOTECH VENTURE FINANCING

PRIVATE EQUITY ROUNDS – 5 YEAR REPORT



Biotech companies are a subset of Life Science companies and include: Biotech - Therapeutic and Diagnostic, Biotech - R&D Services, Biotech – Others. Financing data only includes private equity rounds (excl. private placements in public companies) of biotech companies (incl. therapeutic and diagnostic, R&D services and others). Data may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

MAJOR LIFE SCIENCES VENTURE FINANCING ROUNDS

TOP 5 PRIVATE EQUITY FINANCING ROUNDS | 2024-2026

Company		Sector	Most Advanced Asset Phase	Type of Round	USD M
Neko Health AB		Digital Health	N/A	Series C	\$700
Neko Health AB		Digital Health	N/A	Series B	\$260
NaturalCycles Nordic AB		Digital Health	N/A	Series C	\$55
SmartCella Holding AB		Biotech – Therapeutics	I/II	Other/Unknown	\$53.9
Tandem Health AB		Digital Health	N/A	Series A	\$50

The table shows the five biggest private equity financing rounds (excl. IPOs, research grants, loans) of private and independent life sciences companies from 2024-2026. Information displayed in the table may alter as new information is continuously received and/or new tranches to existing financing rounds are added.

MAJOR BIOTECH M&A DEALS

TOP 5 M&A DEALS | 2025-2026

Entity Acquired	Buyer	Acquisition Type	USD M
Hansa Biopharma AB 	SERB 	Division / asset	\$131.2
Toleranzia AB 	Flerie AB 	Entire company	\$4.8
Pharmacure Health Care 	Nosa Plugs AB 	Entire company	\$2.9
WntResearch AB 	Opsy Holding AB 	Entire company	N/A
Entomed Medtech AB 	Demant A/S 	Entire company	N/A

The table shows the M&A deals of private and independent companies in 2025 and 2026 where the target company was headquartered in Sweden. Information displayed in the table may alter as new information is continuously received.

ABOUT BIOTECHGATE



Biotechgate is a leading **business development and licensing database** for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 46,000 **licensing deals** and a **clinical trials database** containing over 1'000,000 records from registries around the world.

To register for a [free demo](#) or to learn more about the different subscription options, please visit [Biotechgate](#).

BIOTECHGATE DIGITAL PARTNERING

Virtual business development & licensing event
Dec 7 – 11, 2026



www.digitalpartnering.com

TERMS OF USE

The Life Sciences Trend Analysis is based on data entered in the Biotechgate Database available at www.biotechgate.com. The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The use of the figures and graphs provided in this report is free of charge for any presentations as long as www.biotechgate.com is clearly cited as the source. For all other uses please contact us for terms and conditions.



BIOTECHGATE

c/o Venture Valuation VV AG

Kasernenstrasse 11

8004 Zurich

SWITZERLAND



+41 (43) 321 86 60



www.venturevaluation.com

